Loading...

Laboratory Corporation of America Holdings
NYSE:LH

Watchlist Manager
Laboratory Corporation of America Holdings Logo
Laboratory Corporation of America Holdings
NYSE:LH
Watchlist
Price: 218.41 USD +1.75% Market Closed
Updated: Mar 25, 2023

Intrinsic Value

The intrinsic value of one LH stock under the Base Case scenario is 291.8 USD. Compared to the current market price of 218.41 USD, Laboratory Corporation of America Holdings is Undervalued by 25%.

The Intrinsic Value is calculated as the average of the two valuation methods:

LH Intrinsic Value
Base Case
291.8 USD
Undervaluation 25%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Fundamental Analysis

LH Profitability Score
Profitability Due Diligence

Laboratory Corporation of America Holdings's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

Negative 1-Year Revenue Growth
Positive ROIC
Positive Net Income
ROE is Increasing
57/100
Profitability
Score

Laboratory Corporation of America Holdings's profitability score is 57/100. The higher the profitability score, the more profitable the company is.

LH Solvency Score
Solvency Due Diligence

Laboratory Corporation of America Holdings's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Positive Net Debt
High Interest Coverage
Short-Term Liabilities
Long-Term Liabilities
53/100
Solvency
Score

Laboratory Corporation of America Holdings's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Financials

Balance Sheet Decomposition
Laboratory Corporation of America Holdings

Current Assets 4.6B
Cash & Short-Term Investments 430M
Receivables 3B
Other Current Assets 1.2B
Non-Current Assets 15.5B
Long-Term Investments 65.7M
PP&E 3B
Intangibles 12.1B
Other Non-Current Assets 440M
Current Liabilities 3.1B
Accounts Payable 935M
Accrued Liabilities 1.3B
Other Current Liabilities 889M
Non-Current Liabilities 7B
Long-Term Debt 5.1B
Other Non-Current Liabilities 1.9B
Efficiency
29%
Gross Margin
14%
Operating Margin
9%
Net Margin
10%
FCF Margin
Other

LH Capital Structure
Laboratory Corporation of America Holdings

Market Capitalization 19.3B USD
Total Debt 5.1B USD
Minority Interest 18.9M USD
Preferred Equity 0 USD
Cash and Equivalents 430M USD
Short-Term Investments 0 USD
Enterprise Value 24B USD

Wall St
Price Targets

LH Price Targets Summary
Laboratory Corporation of America Holdings

Wall Street analysts forecast LH stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for LH is 292.49 USD with a low forecast of 262.6 USD and a high forecast of 319.2 USD.

Lowest
Price Target
262.6 USD
20% Upside
Average
Price Target
292.49 USD
34% Upside
Highest
Price Target
319.2 USD
46% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

LH Competitors
Laboratory Corporation of America Holdings

LH Suppliers & Customers
Laboratory Corporation of America Holdings

Suppliers Map
Customers Map

Ownership

LH Insider Trading
Buy and sell transactions by insiders

Laboratory Corporation of America Holdings insiders have sold more shares than they have bought in the past 12 months.

During the last 12 months Laboratory Corporation of America Holdings insiders bought 20.3k USD , and sold 17.7M USD worth of shares. The last transaction was made on Mar 25, 2023 by Kirchgraber Paul R (CEO, Covance Drug Development), who sold 2M USD worth of LH shares.

Sold
0-3
months
2.4M USD
3
3-6
months
5.5M USD
2
6-9
months
8.3M USD
2
9-12
months
1.3M USD
2
Bought
0-3
months
0
0 USD
3-6
months
0
0 USD
6-9
months
1
10.2k USD
9-12
months
1
10.2k USD
Cumulative Transactions Amount
Period Sold Bought Net
3 Months
2.4M USD
N/A
-2.4M
6 Months
7.9M USD
N/A
-7.9M
9 Months
16.2M USD
10.2k USD
-16.2M
12 Months
17.6M USD
20.3k USD
-17.5M
Purchases
7
Sales
342
No transactions found
Why is insider trading important?

Shareholder Return

LH Return Decomposition
Main factors of price return

Market capitalization of LH shares increased by 15.3% over the past 5 years. The primary factor behind the change was an increase in revenue growth from 10.7B to 14.9B, leading to a growth in the market capitalization of Laboratory Corporation of America Holdings by 34.99%.

Market capitalization of LH shares increased by 15.3% over the past 5 years. The primary factor behind the change was an increase in revenue growth from 10.7B to 14.9B, leading to a growth in the market capitalization of Laboratory Corporation of America Holdings by 34.99%.

+15.3%
16.7B 19.3B
Market Cap Growth
+9.98%
13.7 15.1
P/E Change
+5.32%
1.2B 1.3B
Earnings Growth
Market Cap Growth
+15.3%
P/E Change
+9.98%
Earnings Growth
+5.32%
What is price return decomposition?

LH Price
Laboratory Corporation of America Holdings

1M 1M
-9%
6M 6M
+4%
1Y 1Y
-20%
3Y 3Y
+79%
5Y 5Y
+33%
Annual Price Range
218.41
52w Low
204.3
52w High
276.29
Price Metrics
Average Annual Return 19.27%
Standard Deviation of Annual Returns 29.9%
Max Drawdown -47%
Shares Statistics
Market Capitalization 19.3B USD
Shares Outstanding 89 000 000
Percentage of Shares Shorted 2.28%

Company Profile

Laboratory Corporation of America Holdings Logo
Laboratory Corporation of America Holdings

Country

United States of America

Industry

Health Care

Market Cap

19.3B USD

Dividend Yield

1.32%

Description

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. The company is headquartered in Burlington, North Carolina and currently employs 75,500 full-time employees. The Company’s business segments include Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). Through its Dx and DD segments, the Company provides diagnostic, drug development and technology enabled solutions. The firm also supports clinical trial activity in approximately 100 countries through its industry central laboratory, preclinical, and clinical development businesses. Dx segment operates through a network of patient service centers, branches, rapid response laboratories, primary laboratories, and specialty laboratories. DD segment, which operates on a global scale. The firm serves a range of customers, including doctors, hospitals, pharmaceutical companies, researchers, governmental agencies, physicians and other healthcare providers. The company also helps in delivering non-clinical testing services.

Contact

NORTH CAROLINA
Burlington
358 S Main St
+13362291127.0
https://www.labcorp.com

IPO

1991-04-24

Employees

75 500

Officers

Pres, CEO & Chairman
Mr. Adam H. Schechter
CFO & Exec. VP
Mr. Glenn A. Eisenberg
Exec. VP, Pres of Diagnostics & Chief Medical Officer
Dr. Brian J. Caveney M.P.H., M.D., J.D., MPH
Exec. VP and Pres of Diagnostics Laboratory Operations & Global Supply Chain
Mr. Mark S. Schroeder
Exec. VP & CEO of Covance Drug Devel.
Dr. Paul R. Kirchgraber M.D.
Laboratory Director of Operations
Dr. Michelle Abelson Ph.D.
Show More
Sr. VP & Chief Accounting Officer
Mr. Peter J. Wilkinson
Exec. VP and Chief Information & Technology Officer
Mr. Lance V. Berberian
Chief Scientific Officer & Sr. VP
Dr. Marcia T. Eisenberg Ph.D.
VP of Investor Relations
Chas Cook
Show Less

See Also

Similar Stocks
What is the Intrinsic Value of one LH stock?

The intrinsic value of one LH stock under the Base Case scenario is 291.8 USD.

Is LH stock undervalued or overvalued?

Compared to the current market price of 218.41 USD, Laboratory Corporation of America Holdings is Undervalued by 25%.